Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Carnival CEO Comments on the Current State of the Cruise Industry

Carnival Corp. Chief Executive Officer Arnold Donald expressed optimism for recovery in the cruise industry, citing pent-up demand from regular cruisers. Donald spoke with Bloomberg’s Ed Hammond about these topics and more. Watch or read the transcript below. — Donald: We [Carnival] have a nice liquidity runway, we’re at the point where we still have…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Carnival CEO Comments on the Current State of the Cruise Industry

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Carnival Corp. Chief Executive Officer Arnold Donald expressed optimism for recovery in the cruise industry, citing pent-up demand from regular cruisers. Donald spoke with Bloomberg’s Ed Hammond about these topics and more. Watch or read the transcript below.

Donald: We [Carnival] have a nice liquidity runway, we’re at the point where we still have additional debt, we could secure if we needed it, and obviously, we will be opportunistic with regards to the balance sheet overall and in terms of equity. And so on. But at this point, we have the liquidity.

We need, you know, for to take us well into next year. And so with zero revenue. And obviously, we’re hoping to have some revenue this year and the beginning, it was a tough time.

You know, some of the debt we raise were at rates, you know, that we never would have even considered in the past. Then even more recent ones are at rates where we’re happy about them now. But, you know, two years ago, we wouldn’t have been happy with those rates.

So it is what it is. But, you know, we’ll adapt. And we have a great resilient business, a great resilient industry.

We will be able to generate lots of cash. And over time, we’ll get back to the solid credit rating that we had prior to the pandemic.

Host: I’m interested in that resilience that you mentioned on, because if I look at this industry, I mean, look, every industry has suffered through COVID. But I think when I think about the cruise industry, there have been some real and very visceral horror stories that have gone on over the last year. I understand you have a sticky customer base, but how do you pitch this as a model to new potential cruises?

Donald: As we look ahead, we have over eight million repeat cruises in our world. And of carnival and our nine world brands. And there’s pent up demand, a cruise on average once every two years.

And so there’s a whole year of repeat cruises basically that haven’t been able to cruise. And so we have plenty of pent up demand. Additionally, we reduced the size of the fleet because obviously, we had ships that were less efficient, and it didn’t make sense when they weren’t generating revenue to continue to invest in those ships.

That’s one way we got our burn rate down. And so we plan to exit 19 ships. So that takes our capacity down when we do come back.

Furthermore, it’s going to be a staggered return. All the destinations aren’t going to open up at once. Different destinations will open at different times.

And so there will be plenty of pent up demand, as is evidenced by the bookings already. As you look at late 2021 and first half, second half of 2022, where the bookings are stronger than they were even prior to COVID on the same basis.

Host: But also, if the cruise from what I understand, this is right, if the cruise of the near future is sort of more people, you know, on these boats in sort of isolation from one another and lose something of its essence, I mean, isn’t the whole allure of going on a cruise that you get these you know, you get to jostle and mingle with strangers, you have this sort of conviviality by the waves. If you don’t have that, then do people really want to go cruising?

Donald: Look, first of all, you’re absolutely right that travel and cruising in particular is about people connecting with other people. What people remember are other people on the cruise ships. The ships are fabulous. We have lots of features, but it’s all about the human spirit and human exchange. And people learn what they have in common. And then they learn to celebrate the differences rather than fear them. And that’s whether it’s through the guests to guests, or guests to the locals of the various destinations that they visit. So you’re absolutely right about that. Having said that, we are ready to resume cruising in Italy and with our Constitution and in Germany on a very limited basis. But our net promoter scores and basically our guest satisfaction scores went through the roof. People love the experience.

*Bloomberg contributed to this content

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512